Pharsight

Drugs that contain Alectinib Hydrochloride

1. Alecensa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9126931 HOFFMANN-LA ROCHE Tetracyclic compound
May, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9440922 HOFFMANN-LA ROCHE Tetracyclic compound
Jun, 2030

(6 years from now)

US9365514 HOFFMANN-LA ROCHE Composition comprising tetracyclic compound
Mar, 2032

(7 years from now)

US10350214 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose
Apr, 2035

(11 years from now)

US11433076 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose
Apr, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-159) Nov 06, 2024
New Indication(I-756) Nov 06, 2020
Orphan Drug Exclusivity(ODE-105) Dec 11, 2022
Orphan Drug Exclusivity(ODE) Nov 06, 2024
New Chemical Entity Exclusivity(NCE) Dec 11, 2020

NCE-1 date: 12 December, 2019

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's drug patent expiration?
More Information on Dosage

ALECENSA family patents

Family Patents